Immunogen Inc (IMGN)
3.81
+0.10
(+2.70%)
USD |
NASDAQ |
Mar 31, 15:19
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 861.24M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -21.89% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 8.883 |
| Price to Book Value | 5.527 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 90.72% |
News
Headline
Wire
Time (ET)
Yahoo
03/29 06:33
Business Wire
03/25 09:00
Yahoo
03/01 13:27
MT Newswires
03/01 09:06
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/05/2023* | -- | Results | Q1 2023 | -- | -0.25 | -- | |
| 05/05/2023* | 08:00 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 03/01/2023 | -- | Results | Q4 2022 | -0.23 | -0.30 | 23.10% | |
| 03/01/2023 | 08:00 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 11/04/2022 | -- | Results | Q3 2022 | -0.31 | -0.25 | -21.78% | |
| 11/04/2022 | 08:00 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 07/29/2022 | 08:00 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 07/29/2022 | -- | Results | Q2 2022 | -0.24 | -0.21 | -13.21% |
*Estimated Date/Time
Earnings
Profile
| Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. |
| URL | https://www.immunogen.com |
| Investor Relations URL | https://investor.immunogen.com |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | May. 05, 2023 (est.) |
| Last Earnings Release | Mar. 01, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 30, 2023.
Fundamentals
| Revenue (TTM) | 108.78M |
| Total Expenses (TTM) | 329.68M |
| Net Income (TTM) | -222.93M |
| Total Assets (Quarterly) | 348.94M |
| Total Liabilities (Quarterly) | 193.11M |
| Shareholders Equity (Quarterly) | 155.83M |
| Cash from Operations (TTM) | -229.80M |
| Cash from Investing (TTM) | -1.364M |
| Cash from Financing (TTM) | 27.55M |
Ratings
Profile
| Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. |
| URL | https://www.immunogen.com |
| Investor Relations URL | https://investor.immunogen.com |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | May. 05, 2023 (est.) |
| Last Earnings Release | Mar. 01, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| F00001CY0Y | 335.00 USD | 3.35% |
| SMHCMX | 246.00 USD | 2.46% |
| PSLBX | 3.170M USD | 1.21% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| IMGN Tweets |